menu
    • menu
    [{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Atebimetinib","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Atebimetinib","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Eli Lilly"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Atebimetinib","moa":"||MAPK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Leerink Partners"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Atebimetinib","moa":"||MAPK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals for Atebimetinib

    Menu

    Atebimetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immuneering Corporation

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atebimetinib,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Leerink Partners

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Immuneering Announces Pricing of $175 Million Underwritten Public Offering

                            Details : The proceeds will be used to advance the preclinical and clinical development of its product candidates, including IMM-1-104 (atebimetinib), functions as a MEK-targeting deep cyclic inhibitor.

                            Product Name : IMM-1-104

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 25, 2025

                            Lead Product(s) : Atebimetinib,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Leerink Partners

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Immuneering Corporation

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atebimetinib,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Sanofi

                            Deal Size : $25.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Immuneering Plans Public Offering and Private Placement with Sanofi

                            Details : The proceeds from the placement will be used to advance the clinical development IMM-1-104 (atebimetinib), which is being evaluated for Pancreatic Neoplasms.

                            Product Name : IMM-1-104

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 24, 2025

                            Lead Product(s) : Atebimetinib,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Sanofi

                            Deal Size : $25.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Immuneering Corporation

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atebimetinib,Olomorasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Immuneering Announces Clinical Supply Agreement with Lilly

                            Details : The supply agreement supports the evaluation of Immuneering’s lead product candidate, atebimetinib (IMM-1-104) in combination with olomorasib in a planned Phase 2 trial in patients with NSCLC.

                            Product Name : IMM-1-104

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 25, 2025

                            Lead Product(s) : Atebimetinib,Olomorasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Immuneering Corporation

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atebimetinib,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $25.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Immuneering Announces $25 Million Private Placement

                            Details : THe proceeds from the financing will used to advance the clinical development of IMM-1-104 (atebimetinib), which is being evaluated for the treatment of pancreatic neoplasms.

                            Product Name : IMM-1-104

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 21, 2025

                            Lead Product(s) : Atebimetinib,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $25.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth